Figure 3.
Figure 3. Hierarchic clustering FLT3-MU samples supervised by clinical outcome: induction refractory and relapse (Group I) versus continuous complete remission (Group II). (A) Hierarchic clustering based on PAM analysis that differentiates FLT3-MUs with inferior (Group I) versus superior (Group II) clinical outcome. PAM analysis of FLT3-MU samples was supervised by clinical outcome, and the analysis identified several genes involved in transcriptional regulation of gene expression. RUNX3 and ATRX genes, 2 known transcriptional regulators, were selected by PAM and SAM as differentially expressed between FLT3-MU with inferior (Group I) and superior (Group II) clinical outcomes. (B) The statistically different EFS between FLT3-MUs with different gene expression signatures (Group I signature vs Group II signature).

Hierarchic clustering FLT3-MU samples supervised by clinical outcome: induction refractory and relapse (Group I) versus continuous complete remission (Group II). (A) Hierarchic clustering based on PAM analysis that differentiates FLT3-MUs with inferior (Group I) versus superior (Group II) clinical outcome. PAM analysis of FLT3-MU samples was supervised by clinical outcome, and the analysis identified several genes involved in transcriptional regulation of gene expression. RUNX3 and ATRX genes, 2 known transcriptional regulators, were selected by PAM and SAM as differentially expressed between FLT3-MU with inferior (Group I) and superior (Group II) clinical outcomes. (B) The statistically different EFS between FLT3-MUs with different gene expression signatures (Group I signature vs Group II signature).

Close Modal

or Create an Account

Close Modal
Close Modal